HTBA: Leading Natural Ingredients Company in a New Growth Phase
Deal News | Jan 06, 2025 | Keyhaven Capital Partners
HealthTech BioActives (HTBA), a global leader in natural ingredient production focusing on citrus flavonoids and vitamin B12, is set for an ambitious growth phase following its acquisition backed by Keyhaven Capital Partners. Keyhaven, a specialist private equity firm in the European lower mid-market, has come together with Miura Partners and Evolve Healthcare Partners to acquire HTBA. This move represents Keyhaven's third investment in 2024 and aims to enhance HTBA's standing in the natural ingredients and health sectors. HTBA, headquartered in Barcelona, Spain, has a significant global presence, selling products in over 60 countries, and operates manufacturing and research facilities in Spain and the US. The firm is known for its innovative, environmentally-conscious production processes. Keyhaven, Miura, and Evolve are committed to driving HTBA's organic and inorganic growth, marking a strategic alignment with their investment philosophies focused on industry-leading and defensive sectors. The collaboration brings together expertise from different PE firms, each contributing unique strengths, aiming to capitalize on HTBA's robust foundation and growth potential through strategic and operational excellence.
Sectors
- Private Equity
- Pharmaceuticals
- Healthcare
- Food and Beverage
Geography
- Spain – Home to HTBA headquarters and part of the European market focus for Keyhaven and Miura Partners.
- United Kingdom – UK-based Keyhaven Capital Partners is pivotal in the acquisition backing.
- United States – HTBA has technical labs in Ohio, indicating the firm's global operational reach and strategic interests.
Industry
- Private Equity – Involving Keyhaven Capital Partners' backing in the acquisition process, this industry forms the basis of the transaction.
- Pharmaceuticals – HTBA specializes in pharmaceutical-grade natural ingredients, positioning this sector as central to its operations.
- Healthcare – Evolve Healthcare Partners' focus and HTBA's role in producing ingredients for health supplements link this industry closely to the narrative.
- Food and Beverage – Apart from pharma, HTBA serves this industry with its natural ingredients, marking its relevance.
Financials
- Over 2.2 billion – Total investment value Keyhaven has advised or invested in across Europe.
- 1.5 billion – Assets currently managed by Miura Partners.
- 4 billion – Total investment value Miura has completed since its inception.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| HealthTech BioActives (HTBA) | Target company | Company | A leader in the production of natural ingredients for multiple industries. |
| Keyhaven Capital Partners | Private Equity Firm | Company | Specialist in the European lower mid-market, backing Miura and Evolve in the HTBA acquisition. |
| Miura Partners | Co-Investor | Company | Private equity firm focused on small to medium-sized businesses, part of the acquisition deal. |
| Evolve Healthcare Partners | Co-Investor | Company | Healthcare-focused private equity firm involved in HTBA's acquisition. |
| Instinctif Partners | PR | Company | PR firm handling media enquiries for Keyhaven. |
| Teddy Mouawad | Partner and Co-Head of Investments | Person | A leader at Keyhaven Capital Partners involved in the transaction commentary. |
| Jordi Sab | Managing Partner | Person | Represents Evolve Healthcare Partners, discussing the strategic alliance. |
| Jordi Alegre | Managing Partner | Person | Represents Miura Partners, commenting on the strategic alignment with HTBA. |